STOCK TITAN

Axcella Health Inc - AXLA STOCK NEWS

Welcome to our dedicated news page for Axcella Health (Ticker: AXLA), a resource for investors and traders seeking the latest updates and insights on Axcella Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axcella Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axcella Health's position in the market.

Rhea-AI Summary
Axcella Therapeutics (Nasdaq: AXLA) approves 1-for-25 reverse stock split to increase per share market price and meet Nasdaq listing requirements. Split-adjusted trading to begin on September 19, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.23%
Tags
none
-
Rhea-AI Summary
Axcella Therapeutics (Nasdaq: AXLA) has been granted a US patent for its Candidate AXA1125, which treats post-acute sequelae of COVID-19 (PASC), specifically fatigue. The patent, issued on August 29, 2023, expands Axcella's global patent portfolio and provides protection for AXA1125 until 2042. This strengthens Axcella's position and validates the formulation's tie to treating Long COVID Fatigue. The company is pursuing options to bring the product forward for the benefit of Long COVID patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
298.23%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.47%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.4%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.53%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50.78%
Tags
none
Axcella Health Inc

Nasdaq:AXLA

AXLA Rankings

AXLA Stock Data

1.18M
1.07M
15.8%
55.8%
2.65%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About AXLA

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.